JC

John Curnutte

Investor

San Francisco Bay Area

Overview 

John Curnutte is a highly accomplished professional serving as a Board Member at Orchard Therapeutics and Pliant Therapeutics, with a background in biotechnology, R&D, and clinical development. He has held significant leadership roles at Portola Pharmaceuticals as Executive Vice President of Research & Development and as CEO at 3-V Biosciences, showcasing his expertise in drug development and biopharmaceuticals.

Work Experience 

  • Board Member

    2024 - Current

Cayuga Biotech develops hemostatic drugs and devices for treating bleeding episodes.

Raised $250,000.00 from IndieBio, SOSV, SOSV and IndieBio.

  • Senior Advisor

    2020

Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies.

  • SAB Member

    2020

Autobahn Labs is a biotechnology company that accelerates the development of novel therapeutics.

  • Board of Directors Member

    2017

  • Board Member

    2019 - 2024

  • Consultant

    2019 - 2020

  • Executive Vice President of Research & Development

    2011 - 2019

Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.

Raised $1,314,100,015.00 from Athyrium Capital Management LP and HealthCare Royalty Partners.

  • CEO

    2008 - 2010

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.

Raised $406,156,611.00 from Invus, Altium Capital, Rock Springs Capital, New Enterprise Associates, Ascletis, Huimei Capital, PFM Health Sciences and Kleiner Perkins.

  • Senior Director, Department of Immunology

    1993 - 2000

  • Associate Professor (Tenured)

    1986 - 1993

Articles About John

Relevant Websites